Delving into the Latest Updates on Prasugrel Hydrochloride/Aspirin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aspirin/Prasugrel, Prasugrel/aspirin

Target

COX x P2Y12 receptor

Mechanism

COX inhibitors(Cyclooxygenases inhibitors), P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Acute Coronary Syndrome

Inactive Indication-

Originator Organization

Torrent Pharmaceuticals Ltd.

Active Organization

Torrent Pharmaceuticals Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

IN (01 Jan 2016),

Acute Coronary Syndrome

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC9H8O4

InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N

CAS Registry50-78-2

View All Structures (2)

This study is multi-center, open label, two-by-two factorial, randomized, noninferiority trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated stents (BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of aspirin plus prasugrel with 12-month DAPT of aspirin plus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Start Date17 Jan 2022

Sponsor / Collaborator

Samsung Medical Center

NCT00827411 / CompletedPhase 4

Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting

Our first hypothesis is that dose adjustment of aspirin and clopidogrel based on biological monitoring reduces the rate of severe cardiovascular complications compared to a conventional strategy in patients scheduled for drug eluting stent implantation and followed up for one year. Our second hypothesis is that interruption of clopidogrel / Prasugrel after one year of a combined therapy of clopidogrel/Prasugrel and aspirin is associated with a higher rate of severe cardiovascular complications as compared with patients in whom aspirin and clopidogrel / Prasugrel is maintained during the subsequent 6 months of follow-up.

Start Date01 Jan 2009

Sponsor / Collaborator